AstraZeneca is "Undervalued" Say Analysts

Morningstar analysts have upgraded the pharmaceutical company to four stars - rating it as undervalued. Could this be a buying opportunity?

Damien Conover, CFA 8 August, 2013 | 8:45AM

AstraZeneca (AZN) reported second-quarter results that largely met both our expectations and those of consensus. We don't expect any significant changes to our fair value estimate based on the results. Further, while we believe Astra's wide moat remains intact based on a robust lineup of currently marketed drugs and an emerging pipeline, the company's negative moat trend was highlighted in the quarter with intense generic competition that should not subside for several years.

In the quarter, total sales fell 4% year over year due to patent losses, and we expect this pressure to intensify over the next three years. Patent losses on gastrointestinal drug Nexium and cardiovascular drug Crestor in 2014 and 2016, respectively, will likely create a long-term drag on the company. While new product launches are helping to mitigate the generic headwinds, we don't expect the company to return to growth for several years. On the new product side, we are most enthusiastic about cardiovascular drug Brilinta, which holds blockbuster potential, but has been off to a slow start. Also, we expect diabetes drugs Onglyza and Forxiga to eventually develop into blockbusters.

Turning to the pipeline, Astra is making several acquisitions, helping to offset internal pipeline setbacks. We believe the recent Pearl acquisition will help further entrench Astra's respiratory franchise with the important new class of drug LABA/LAMA, which should help Astra keep up with competitors. The new respiratory addition should also make up for lost growth potential due to the Phase III failure of fostamatinib for rheumatoid arthritis. Overall, we expect Astra will need further acquisitions to deal with its long and steep patent cliff.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

To view this article, become a Morningstar Basic member.

Register For Free

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Securities Mentioned in Article

Security NamePriceChange (%)Morningstar
Rating
AstraZeneca PLC7,876.00 GBX-0.05

About Author

Damien Conover, CFA  is an equity analyst and associate director at Morningstar.

Audience Confirmation


By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies